SRT1720

Catalog No.S1129

SRT1720 Chemical Structure

Molecular Weight(MW): 506.02

SRT1720 is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3.

Size Price Stock Quantity  
In DMSO USD 238 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • EMBO J 2013 32, 791-804. SRT1720 purchased from Selleck.

    Sirt1 deacetylase activity is essential for IRF9-mediated ischemic injury. The effects of SRT1720 on Sirt1 deacetylase activity in IRF9-KO and IRF9-TG mice, respectively. *p < 0.05 versus DMSO controls. n = 5.

    J Neurosci 2014 34(36), 11897-912. SRT1720 purchased from Selleck.

  • PAI-1 expression in HUVECs treated with drugs as indicated.(D) senescent HUVECs were treated with SRT1720, culturing for 24, 48 hours. PAI-1 mRNA and protein (E) levels were analyzed using real-time RT–PCR and Western blotting, respectively. The RNA and protein levels were normalized to the internal control β-actin. Data are presented as the mean±SEM of three independent experiments. *P < 0.05 vs. corresponding control. **P < 0.01 vs. corresponding control ***P < 0.001 vs. corresponding control.

    Aging Cell 2014 13(5), 890-9. SRT1720 purchased from Selleck.

    C2C12 myoblasts were transfected with si-CON and si-NDUFV1 for 24 h and then further differentiated into myotubes for 4 days in the absence or presence of pyruvate (25 mM), SRT1720 (2 uM), or resveratrol (Resv; 25 uM). Myogenesis was monitored using MyHC immunofluorescence and DAPI.

    J Biol Chem 2014 289(29), 20012-25. SRT1720 purchased from Selleck.

  • J Biol Chem 2012 287, 19304-19314. SRT1720 purchased from Selleck.

Purity & Quality Control

Choose Selective Sirtuin Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description SRT1720 is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3.
Targets
SIRT1 [1]
(Cell-free assay)
0.16 μM(EC50)
In vitro

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. SRT1720 could reduce fed glucose levels. Glucose excursion during an intraperitoneal glucose tolerance test is also significantly reduced in the SRT1720 group, and comparable to rosiglitazone, a PPARγ activator that has been used to treat type 2 diabetes. SRT1720 does not have an effect on fasting glucose in chow-fed mice, revealing that pharmacological SIRT1 activation is unlikely to induce hypoglycaemia. SRT1720 significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing increased insulin levels similar to rosiglitazone treatment. SRT1720 treatment increases mitochondrial capacity by 15% in gastrocnemius muscle as measured by citrate synthase activity. [1] Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CACs  MWfGeY5kfGmxbjDBd5NigQ>? MoW4OOKh|ryP MmHNN|DDqG2rbh?= NYTyRpk{TE2VTx?= NFvvcJRqdmS3Y3XzJIFkfXSnIGPJVnQyKGGldHn2ZZRqd28EoB?= NUPBc5E5OjZ{NUSxNFQ>
MC3T3-E1 MYjGeY5kfGmxbjDBd5NigQ>? M{Xv[|ExKML3TdMg NV;3eZV{OSCq M{LYbpJm\HWlZYOgeIhmKFSJRj5Otk1{fGmvdXzheIVlKF[HR1[gdoVt\WG|ZTDpckBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{wrC= M2nUelI3OTN4OUe4
MC3T3-E1 NVWwO2tNTnWwY4Tpc44hSXO|YYm= M3PEblExKML3TdMg NHHmPZAyOiCq MUTy[YR2[2W|IITo[UBXTUeIIH3SUmEh\XiycnXzd4lwdiCuZY\lcJMhe3SrbYXsZZRm\CCkeTDUS2Yu|rJ? NWLvUJBMOjZzM{[5O|g>
MC3T3-E1 MX\GeY5kfGmxbjDBd5NigQ>? NIDlSlEzOCEQvF2= MYixJIg> MVHzeZBxemW|c3XzJJRp\SCWR1[t{tIucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDR2L4C0NkBOSVBia3nuZZNmKG:{IGPBVGswUk6N NW\lVYV7OjZzM{[5O|g>
WE-68 NFLDXXJCeG:ydH;zbZMhSXO|YYm= NH\qNWcxNTJ2IN88US=> MXeyOEBp NVHMTodZcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHTvd4Uh\GWyZX7k[Y51dHl? MoS5NlYxPTV6MEW=
SK-ES-1 MXTBdI9xfG:|aYOgRZN{[Xl? NFzufFAxNTFyIN88US=> M{fibVI1KGh? NX3CVFhqcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHTvd4Uh\GWyZX7k[Y51dHl? MUSyOlA2PThyNR?=
SK-N-MC  NULoT|BYSXCxcITvd4l{KEG|c3H5 NYDmNIxXOC1{LkWg{txO M1;5PFI1KGh? NWHSXIJMcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHTvd4Uh\GWyZX7k[Y51dHl? NXfnWHhqOjZyNUW4NFU>
WE-68 NV7HSFdTTnWwY4Tpc44hSXO|YYm= MXiyNEDPxE1? Mn7ZNE0zPCCq NH3IPGJi[3SrdnH0[ZMh[2G|cHHz[UA{Nzd? MYOyOlA2PThyNR?=
SK-ES-1 NH7O[3dHfW6ldHnvckBCe3OjeR?= MWixNEDPxE1? MkL2NE0zPCCq NEjSbFli[3SrdnH0[ZMh[2G|cHHz[UA{Nzd? MkK3NlYxPTV6MEW=
SK-N-MC  NETLbGVHfW6ldHnvckBCe3OjeR?= NXfxeJZoOyEQvF2= NXTSWohKOC1{NDDo M4P1c4FkfGm4YYTld{Bk[XOyYYPlJFMwPw>? NHTodpUzPjB3NUiwOS=>
NRK-49F NVPCN41WTnWwY4Tpc44hSXO|YYm= MWWw5qCUOsLizszN M1[0blM3KGh? M2\HW4lv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIN8xMXNOSSCjbnSg[oljem:wZXP0bY4h\G:|ZTDk[ZBmdmSnboTsfS=> MnfONlYxOjJyMEO=
NRK-49F MVrGeY5kfGmxbjDBd5NigQ>? M2nGN|DjiJN{wrFOwG0> M{TUSVM3KGh? MWnlcohidmOnczDwbI9{eGixconsZZRqd25ib3[gSWdHWiCjbnSgVGRITlMQstMg MXyyOlAzOjByMx?=
NRK-49F M3\xc2Z2dmO2aX;uJGF{e2G7 MUWw5qCUOsLizszN M3X6V|M3KGh? MUHlcohidmOnczDTWGFVOyCyaH;zdIhwenmuYYTpc44> Mm\0NlYxOjJyMEO=
RAW264.7 NVLVSGk1TnWwY4Tpc44hSXO|YYm= M2rwNVEh|ryP MVW2JIg> MVf1dJJm\3WuYYTld{B1cGVicnXkeYNm\CCVSWLUNUBxem:2ZXnuJI9zKG2UTlGgcIV3\Wy|IHL5JIhq\2hiZ3z1Z49{\Q>? M4fpZVI2Pzl|OUm1
MCF10A M2j2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW0[|UxNTJyIN88US=> NIfJS3gzPCCq NIDEUVVz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NWDa[oRnOjV2MUGzOVY>
MCF-7 M3jubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXuZ5FVOC1{MDFOwG0> M3vwOVI1KGh? NIPBVnZz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MlnONlU1OTF|NU[=
T47D NYfW[oxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPQfot4OC1{MDFOwG0> M2DWWFI1KGh? MmDIdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NVq1NlZPOjV2MUGzOVY>
SKBR3 M{HOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX0b20xNTJyIN88US=> MmHwNlQhcA>? M2f0[ZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? Ml3FNlU1OTF|NU[=
MDA-MB-231 Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLoWnExNTJyIN88US=> NIPuUZozPCCq NVGzZpdwemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NX3u[G1DOjV2MUGzOVY>
SUM149 NEL6OmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP6NE0zOCEQvF2= MUmyOEBp M{HvR5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MoXQNlU1OTF|NU[=
HS578T NEfqeI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDMWJpvOC1{MDFOwG0> MmLnNlQhcA>? M3u1NpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MXSyOVQyOTN3Nh?=
BT20 NFvUbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml2zNE0zOCEQvF2= Mn\WNlQhcA>? NYS2UIZremWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 Mli2NlU1OTF|NU[=
A459 NUjKeIxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:wMVIxKM7:TR?= M1qzclI1KGh? NXewb5JKemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M17KXVI2PDFzM{W2
HCT116 NHLWNnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVywMVIxKM7:TR?= MVOyOEBp MoTadoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NG\5OZMzPTRzMUO1Oi=>
Neu NYHtUphVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnINE0zOCEQvF2= Mn34NlQhcA>? NXnJO4pkemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M2f0SlI2PDFzM{W2
MDA-MB-231 MkP0SpVv[3Srb36gRZN{[Xl? MV21JO69VQ>? M3zDXVghcA>? M2jKe4lv[3KnYYPld{B1cGViboXtZoVzKG:oIHHjbYRq[yC4ZYPpZ5Vt[XJib4LnZY5mdGyncx?= MYeyOVQyOTN3Nh?=
MDA-MB-231 NFjD[JhHfW6ldHnvckBCe3OjeR?= M3\sclUh|ryP Mn3LNVYhcA>? NWG5d4x1cW6mdXPld{BtgXOxc3;tZYwhdWWvYoLhcoUheGW{bXXhZoltcXqjdHnvci=> M3mzNFI2PDFzM{W2
MC3T3-E1 NYH2b3J[TnWwY4Tpc44hSXO|YYm= NGqydmgyOCEQvF2= MVK2NEBucW8EoB?= M{\rOJN2eHC{ZYPz[ZMhfGinIF\HSk0zNXO2aX31cIF1\WRib4P0[Y9xem:2ZXfldolvKHKnbHXhd4U> MX[yOVI6ODB7NR?=
MC3T3-E1 MojXSpVv[3Srb36gRZN{[Xl? NXv6Nlk5OTBizszN NIexZmg3OCCvaX9CpC=> NHzk[5RifHSnboXheIV{KHSqZTDGS2YuOi2rbnT1Z4VlKG:|dHXvdJJwfGWpZYLpckBuWk6DIHX4dJJme3Orb36= NFrLWY8zPTJ7MEC5OS=>
MC3T3-E1 NFfUXWdHfW6ldHnvckBCe3OjeR?= MYexNEDPxE1? NW\NS3pEPjBibXnuxsA> NFTXd|BifHSnboXheIV{KHSqZTDGS2YuOi2rbnT1Z4VlKG:|dHXvdJJwfGWpZYLpckBuWk6DIHX4dJJme3Orb36= NYXMV4JzOjV{OUCwPVU>
MC3T3-E1 Mly4SpVv[3Srb36gRZN{[Xl? MVOxNEDPxE1? NXLrVIRTPjBibXnuxsA> NWnOSoNre3WycILld5NmeyC2aHWgRm1RNTRvc4TpcZVt[XSnZDDWSWdHKHKnbHXhd4U> M1PzWVI1PDN3NES0
MC3T3-E1 MWfGeY5kfGmxbjDBd5NigQ>? NW[4V2U{OTBizszN MVS2NEBucW8EoB?= NFn4W5J{fXCycnXzd4V{KHSqZTDQS2Yz|rFvc4TpcZVt[XSnZDDPVGchemWuZXHz[S=> NXzObmljOjR|M{OzN|Y>
MC3T3-E1 NX60OWE2TnWwY4Tpc44hSXO|YYm= Moe5NVAh|ryP MmC3OlAhdWmwwrC= MV3y[YR2[2W|IITo[UBRT0Z{zsGtd5RqdXWuYYTl[EBxcG:|cHjvdplt[XSrb36gc4YheDR2L4C0NkBOSVBia3nuZZNm NFTtS4gzPDN|M{OzOi=>
MC3T3-E1 NVeyUGt3TnWwY4Tpc44hSXO|YYm= NXzu[FYzOTBizszN MUO2NEBucW8EoB?= NXnDe|Jy[XS2ZX71ZZRmeyC2aHWgVGdHOs7zLXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIHLveIghVUWNMT:yJIFv\CCUYX[tNS=> MnfUNlQ{OzN|M{[=
RPE NI\ieGpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1;2dFUhyrWP M4DmclEhcA>? MUnheJRmdnWjdHXzJG9C|rJvaX7keYNm\CCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gQ>? MmPSNlQxOzZ7M{i=
9607 MlPiR4VtdCCYaXHibYxqfHliQYPzZZk> M{LoRVEh|ryP MnHLN|YhcA>? MV;pcoNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwdXCjcnXkJJdqfGhibXXsZZRwdmmwIHHsc45m MYCyN|czPjl2OR?=
9607 NYLSc|NxTnWwY4Tpc44hSXO|YYm= M4DtO|Eh|ryP MXKzOkBp MonIbY5kemWjc3XzJHNKWlRzIHHu[EBl\WO{ZXHz[YQh[WOndInsZZRm\C2yNUOg[ZhxemW|c3nvci=> NYT0VGdXOjN5Mk[5OFk>
RPMI.8226 NXexWJQ5S2WubDDWbYFjcWyrdImgRZN{[Xl? MYm3M|ExKM7:TR?= M1fDb|I1KGh? MUXk[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MXKyNVk2ODd{OB?=
U266 NVTNZZBpS2WubDDWbYFjcWyrdImgRZN{[Xl? NWrl[Yg6Py9zMDFOwG0> NHLrVYQzPCCq MmXu[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 NUjYVWZMOjF7NUC3Nlg>
MM.1S MlLSR4VtdCCYaXHibYxqfHliQYPzZZk> MlH5O{8yOCEQvF2= MYGyOEBp NW[3dXZv\GWlcnXhd4V{KH[rYXLpcIl1gSClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 NWfD[mlZOjF7NUC3Nlg>
KMS12 M17Y[WNmdGxiVnnhZoltcXS7IFHzd4F6 NWj3UlNnPy9zMDFOwG0> NHnRSpQzPCCq MYnk[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= M3fPUlIyQTVyN{K4
LR5 Mlf1R4VtdCCYaXHibYxqfHliQYPzZZk> M4fpSFcwOTBizszN MkHpNlQhcA>? NHmw[3Zl\WO{ZXHz[ZMhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> NHfrblkzOTl3MEeyPC=>
MM.1R MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX60UI8{Py9zMDFOwG0> M4PxNlI1KGh? NEHwR|hl\WO{ZXHz[ZMhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> Mnv4NlE6PTB5Mki=
Ina6 M1vPc2NmdGxiVnnhZoltcXS7IFHzd4F6 MlrlO{8yOCEQvF2= M1zkcVI1KGh? NUm0c|Z2\GWlcnXhd4V{KH[rYXLpcIl1gSClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 MYWyNVk2ODd{OB?=
RPMI-8226 NVv6THRESXCxcITvd4l{KEG|c3H5 NX62dGN{Py9zMDFOwG0> MkXtNlQhcA>? MVLpcoR2[2W|IHGgd4lodmmoaXPhcpQhcW6lcnXhd4UhcW5idHjlJGFvdmW6aX6gWkswWEokiKNCpIFxd3C2b4Ppdy=> M4LGUFIyQTVyN{K4
MM.1R  M3f6R2Fxd3C2b4Ppd{BCe3OjeR?= NX;XO|lRPy9zMDFOwG0> MXGyOEBp MljqbY5lfWOnczDhJJNq\26rZnnjZY51KGmwY4LlZZNmKGmwIITo[UBCdm6neHnuJHYsN1CL4pkSxsBieG:ydH;zbZM> MnfvNlE6PTB5Mki=
H411EC3 MV3GeY5kfGmxbjDBd5NigQ>? MkLqOVAwOTByIH7N MkjhOkBp MXfpcoNz\WG|ZYOgV2lTXDFiYXP0bZZqfHliaX6geIhmKHC{ZYPlcoNmKG:oIGTTRUwhWEWSQ1ugZYN1cX[rdImsJI1TVkFibHX2[Yx{KG:oIGDjb|Eh[W6mIGDnZ|HPuSxiYX7kJIVt\X[jdHnu[{BodHWlb4PlJJBzd2S3Y4Tpc44> M3rKbVIyOjF{MEm2
hepatocytes M4DuOmZ2dmO2aX;uJGF{e2G7 NF22SHgyOCCwTR?= MmO2OkBp MWfpcoNz\WG|ZYOgV2lTXDFiYXP0bZZqfHliaX6geIhmKHC{ZYPlcoNmKG:oIGTTRUwhWEWSQ1ugZYN1cX[rdImsJI1TVkFibHX2[Yx{KG:oIGDjb|Eh[W6mIGDnZ|HPuSxiYX7kJIVt\X[jdHnu[{BodHWlb4PlJJBzd2S3Y4Tpc44> NYS4T2RVOjF{MUKwPVY>
hepatocytes NVXvPVdsTnWwY4Tpc44hSXO|YYm= NV3WbHNYOTBibl2= MoDtOkBp NIG4V2RqdmO{ZXHz[ZMhUG2pY4NCpIFv\MLiQXPjxsBo\W6nIHX4dJJme3Orb36= MnrLNlEzOTJyOU[=

... Click to View More Cell Line Experimental Data

In vivo In DIO mice SRT1720 mimics several of the effects observed after calorie restriction including improved insulin sensitivity, normalized glucose and insulin levels, and increased mitochondrial capacity. In addition, in diet-induced obese and genetically obese mice, SRT1720 improves insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes. Consistent with improved glucose tolerance, the glucose infusion rate required to maintain euglycaemia is approximately 35% higher in SRT1720-treated fa/fa rats, and the total glucose disposal rate is increased by approximately 20%. [1] SRT1720 also prevents multiple myeloma tumor growth. SRT1720 increases the cytotoxic activity of bortezomib or dexamethasone. [2]

Protocol

Kinase Assay
+ Expand

SIRT1 fluorescence polarization assay:

In the SIRT1 FP assay, SIRT1 activity is monitored using a 20 amino acid peptide (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly–Lys(MR121 or Tamra)-Glu-Glu-NH2) derived from the sequence of p53. The peptide is N-terminally linked to biotin and C-terminally modified with a fluorescent tag. The reaction for monitoring enzyme activity is a coupled enzyme assay where the first reaction is the deacetylation reaction catalyzed by SIRT1 and the second reaction is cleavage by trypsin at the newly exposed lysine residue. The reaction is stopped and streptavidin is added in order to accentuate the mass differences between substrate and product. The sensitivity of the FP assay allows identification of SRT1720. The fluorescence polarization reaction conditions are as follows: 0.5 μM peptide substrate, 150 μM βNAD+, 0-10 nM SIRT1, 25 mM Tris-acetate pH 8, 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl 2, 5 mM DTT, 0.025% BSA, and 0.15 mM nicotinamide. The reaction is incubated at 37 °C and stopped by addition of nicotinamide, and trypsin is added to cleave the deacetylated substrate. This reaction is incubated at 37 °C in the presence of 1 μM streptavidin. Fluorescent polarization is determined at excitation (650 nm) and emission (680 nm) wavelengths.
Cell Research
+ Expand
  • Cell lines: Human vascular endothelial cells (HUVECs)
  • Concentrations: 5 μM
  • Incubation Time: 2 hours
  • Method: Transwell Insert Assays are utilized to measure migration. In vitro angiogenesis is assessed by Matrigel capillary-like tube structure formation assay. For endothelial tube formation assay, human vascular endothelial cells (HUVECs) are obtained from Clonetics and maintained in endothelial cell growth medium-2 containing 5% FBS. After three passages, HUVEC cell viability is measured with the trypan blue exclusion assay, and <5% of cell death is observed with SRT1720 treatment.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Chase-SCID mice with MM.1S cells
  • Formulation: 20% PEG400/0.5% Tween80/79.5% deionized water
  • Dosages: 200 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (75.09 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 506.02
Formula

C25H23N7OS.HCl

CAS No. 1001645-58-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Sirtuin Signaling Pathway Map

Related Sirtuin Products

Tags: buy SRT1720 | SRT1720 supplier | purchase SRT1720 | SRT1720 cost | SRT1720 manufacturer | order SRT1720 | SRT1720 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID